Why is "Narcolepsy" trending?

Search Interest Perspective

• FDA approves Orzeyful for narcolepsy type 1 in adults - American Academy of Sleep Medicine | AASM
• Institute Publishes Evidence Report on New Narcolepsy Treatment - Sleep Review
• The Race to Come Up With the Next Big Sleep Drug - WSJ
• New in Narcolepsy: Pharmacology Updates - Psychiatric Times
• Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful - Fierce Pharma
• Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments - STAT
• Physician Views Results: Clinician feedback strongly suggests Takeda's Orzeyful is a game-changer for narcolepsy - FirstWord Pharma
• FDA Approves First-in-Class Narcolepsy Drug - medpagetoday.com
• FDA approves first-in-class drug to treat narcolepsy - Drug Discovery News
• FDA Approves Oveporexton, First Orexin Receptor Agonist for Narcolepsy Type 1 - Patient Care Online
• Takeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead - Pharmaceutical Technology
• Takeda’s narcolepsy nod opens orexin doors - BioSpace
• FDA approves Orzeyful, first drug to treat all symptoms of narcolepsy type 1 - Managed Healthcare Executive
• Recon: FDA approves first drug for type 1 narcolepsy, mRNA flu vaccine; No merger talks between AstraZeneca-BMS - raps.org
• FDA Approves Orexin Agonist Oveporexton for Narcolepsy Type 1 - NeurologyLive
• Takeda approval ushers in new wave of sleep drugs - BioPharma Dive
• FDA Approves Orezeyful for Narcolepsy Type 1 in Adults - Pharmaceutical Executive
• FDA Approves Oveporexton for Adults With Narcolepsy Type 1 - HMP Global Learning Network
• Spotlight On: Takeda breaks new ground with narcolepsy approval as Alkermes and Eli Lilly wait in slipstream - FirstWord Pharma
• Physician Views Preview: Orzeyful arrives — Will Takeda's drug redefine narcolepsy treatment? - FirstWord Pharma
• The FDA Approved A New Drug For Narcolepsy. Here’s Why Patients Call It ‘Historic’ - forbes.com
• FDA Okays First-in-Class Narcolepsy Drug Oveporexton - Medscape
• Takeda's first-in-class narcolepsy drug claims FDA approval - pharmaphorum
• FDA Approves Orzeyful, First Drug Targeting Underlying Cause of Narcolepsy - Drug Topics
• FDA approves Takeda’s first-in-class narcolepsy drug - EMJ
• FDA Approves Oveporexton (Orzeyful) for Narcolepsy Type 1 - HCPLive
• FDA Approves Orzeyful for Narcolepsy Type 1 - respiratory-therapy.com
• FDA approves first drug for full range of narcolepsy symptoms - medicalxpress.com
• FDA approves new drug for narcolepsy type 1 symptoms - upi.com
• Fierce Pharma Asia—Takeda’s historic narcolepsy nod; Daiichi’s accounting error; Astellas’ revenue beat - Fierce Pharma
• FDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of NT1 Symptoms - Psychiatric Times
• The brain may be about to have its Ozempic moment - The Economist
• US FDA approves Takeda's sleep disorder pill - Reuters
• Takeda's orexin-targeting Orzeyful wins FDA nod for narcolepsy - FirstWord Pharma
• Orexin receptor agonists set to propel narcolepsy treatment into a new era - Pharmaceutical Technology
• FDA Approves Oveporexton for Narcolepsy Type 1 - Pharmacy Times
• The First Narcolepsy Drug That Treats the Underlying Disease Is Approved but Not Yet Available to Patients - Medical Daily
• FDA Approves First Orexin-Targeting Drug for Narcolepsy Type 1 - Sleep Review
• Takeda’s Orzeyful approved in US as first-in-class orexin treatment for narcolepsy Type 1 - European Pharmaceutical Review
• Narcolepsy is (not) an autoimmune disease - Nature
• Chasing the Dream: How One Player Learned to Thrive with Narcolepsy - Ultiworld
• Human narcolepsy is linked to degeneration of both locus coeruleus and hypocretin neurons - Nature
• FDA Approves First Drug for Full Range of Narcolepsy Symptoms - HealthDay
• Severe narcolepsy found to damage a second brain region - UCLA Health
• FDA grants breakthrough designation for narcolepsy drug alixorexton - American Academy of Sleep Medicine | AASM
• Let the orexin market begin: Takeda snags FDA approval for narcolepsy type 1 drug - Endpoints News
• Why laughter can trigger sudden muscle weakness in people with narcolepsy - medicalxpress.com
• Novel Patient-Reported Outcome Instrument Developed to Measure Functional Impacts of Narcolepsy - Docwire News
• Should FDA Approval of ORZEYFUL for Narcolepsy Type 1 Prompt Action From Takeda Pharmaceutical (TSE:4502) Investors? - simplywall.st
• Celltrion Joins Global Race for Narcolepsy Drugs - Seoul Economic Daily
• FDA greenlight for Takeda's narcolepsy drug Orzeyful - The Pharma Letter
• Takeda gets first OK for orexin narcolepsy drug, in China - pharmaphorum
• Morning Rounds: News From August 3-9 - Psychiatric Times
• Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine - Frontiers
• Takeda wins U.S. FDA approval for narcolepsy drug ORZEYFUL - International Business Times
• FDA Approves First Drug To Treat Narcolepsy Type 1 Symptoms - RTTNews
• Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments - The Boston Globe
• FDA Accepts NDA for AXS-12 for the Treatment of Cataplexy in Narcolepsy - Psychiatric Times
• FDA Approves First-in-Class Narcolepsy Drug - Labroots
• Oveporexton Shows Gains in Cognition, Sleep Quality in Narcolepsy: Elena Koundourakis, PhD - The American Journal of Managed Care
• Yomiuri: Japan Set to Approve Drug that Treats Narcolepsy - marketwatch.com
• Lundbeck secures FDA Fast Track for narcolepsy drug - PharmaTimes
• Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval - Benzinga
• Evaluating the Impact of Oveporexton in Phase 3 Studies for Narcolepsy Type 1: Elena Koundourakis, PhD - NeurologyLive
• Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy - Sleep Review
• FDA approves Wakix for cataplexy in pediatric narcolepsy - American Academy of Sleep Medicine | AASM
• New Narcolepsy Drug Signals a Shift From Symptom Management to Disease-Based Treatment - Medical Daily
• FDA Approves First Narcolepsy Drug That Targets the Brain Signal Loss Behind the Disorder - Medical Daily
• U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 - Business Wire
• Orexin Agonist Shows Promise for Treating Narcolepsy, Hypersomnia: Richard Bogan, MD - The American Journal of Managed Care
• Development of Narcolepsy Type 1 Following COVID-19 Infection in a Patient Previously Diagnosed With Idiopathic Hypersomnia: A Case Report - Cureus
• Alkermes CEO sees 'inflection point' as company races for first blockbuster drug - The Business Journals
• Insights on Vibrance-2 Study Results of Alixorexton in Narcolepsy Type 2: Richard K. Bogan, MD, FCCP, FAASM - NeurologyLive
• Alixorexton for the Treatment of Narcolepsy Type 2: Insights From SLEEP 2026 - Psychiatric Times
• Narcolepsy raises your risk of depression, anxiety and social isolation. Why? - Mayo Clinic Press
• Individualizing Narcolepsy Care: Real-World Oxybate Outcomes - Psychiatric Times
• MedCheck: FDA Reviews NDA for Narcolepsy Drug, Green-Lights Psilocybin Trial for PTSD, and More - Psychiatry Online
• Narcolepsy-like pathologic daytime sleepiness in a patient with obsessive-compulsive disorder and attention deficit hyperactivity disorder: a Case Report - Frontiers
• Alkermes Launches Phase 3 Brilliance Program for Alixorexton in Narcolepsy - NeurologyLive
• Your guide to narcolepsy treatments and side effects, according to a sleep medicine expert - Mayo Clinic Press
• FDA Grants Orexin Agonist Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1 - NeurologyLive
• ASPIRE Survey Study Results: New Insights on Patients With Narcolepsy & Idiopathic Hypersomnia - Psychiatric Times
• Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders - Eli Lilly and Company
• Narcolepsy Treatment Considerations in Pediatric Patients - Psychiatric Times
• Reviewing the Prevalence and Underdiagnosis of Narcolepsy - NeurologyLive
• Oveporexton Improves Cognition in Narcolepsy Type 1 - Psychiatric Times
• FDA Grants Fast Track Designation to Investigational Narcolepsy Treatment - Sleep Review
• Takeda wins FDA approval for first drug to treat full range of narcolepsy type 1 symptoms - PharmaLive
• NeuroVoices: Jerome Siegel, PhD, on Locus Coeruleus Neuron Loss as a Key Pathologic Feature of Narcolepsy - NeurologyLive
• Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy - Yahoo Finance
• Why Narcolepsy Is Often Missed—and How to Spot It - Psychiatry Online
• MRI Study Reveals Hypothalamic Atrophy Across Multiple Subregions in Narcolepsy Type 1 - The American Journal of Managed Care
• Identifying Narcolepsy in Psychiatric Populations - Psychiatric Times
• Diagnosing narcolepsy: What to know about polysomnograms and multiple sleep latency tests - Mayo Clinic Press
• Video: High-Dose Low-Sodium Oxybate for Narcolepsy—AAN 2026 Expert Insights - Neurology Advisor
• Why the Orzeyful Approval Matters Beyond One Drug Class - PharmTech.com
• A conversation exploring the newest discovery in narcolepsy research, with sleep researcher Jerome Siegel, Ph.D. - Managed Healthcare Executive
• Understanding Narcolepsy as More Than a Sleep Disorder - NeurologyLive
• FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review - NeurologyLive
• FDA Grants Priority Review to Oveporexton for Narcolepsy Type 1 - Psychiatry Advisor